Medpace Holdings, Inc. (MEDP): Price and Financial Metrics
Medpace Holdings, Inc. (MEDP)
Today's Latest Price: $134.41 USD
Updated Jan 28 11:18am
Add MEDP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 78 in Medical - Services
See all "A" rated Strong Buy stocks
MEDP Stock Summary
- MEDP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 165.8 -- higher than 80.78% of US-listed equities with positive expected earnings growth.
- Medpace Holdings Inc's stock had its IPO on August 11, 2016, making it an older stock than just 15.64% of US equities in our set.
- With a year-over-year growth in debt of 140.47%, Medpace Holdings Inc's debt growth rate surpasses 90.9% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Medpace Holdings Inc are HCKT, PIPR, III, HLI, and CNS.
- MEDP's SEC filings can be seen here. And to visit Medpace Holdings Inc's official web site, go to www.medpace.com.
MEDP Stock Price Chart Interactive Chart >
MEDP Price/Volume Stats
Current price | $134.41 | 52-week high | $150.57 |
Prev. close | $132.02 | 52-week low | $58.72 |
Day low | $132.08 | Volume | 22,194 |
Day high | $134.73 | Avg. volume | 183,563 |
50-day MA | $136.15 | Dividend yield | N/A |
200-day MA | $113.22 | Market Cap | 4.81B |
Medpace Holdings, Inc. (MEDP) Company Bio
Medpace, Inc. operates as a contract research organization that provides research based drug and medical device development services. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Price Forecast Based on DCF Valuation
Current Price | DCF Fair Value Target: | Forecasted Gain: |
$134.41 | $88.35 | -33% |
Below please find a table outlining a discounted cash flow forecast for MEDP, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Medpace Holdings Inc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Medpace Holdings Inc, consider:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Notably, its equity weight is greater than 81.8% of US equities in the Healthcare sector yielding a positive free cash flow.
- The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 10.73% of the free cash flow producing stocks we're observing.
- Medpace Holdings Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -206.25. This coverage rate is greater than that of only 1.24% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
0% | -34% |
1% | -34% |
2% | -33% |
3% | -32% |
4% | -32% |
5% | -31% |
QDEL, STE, AMGN, INBP, and NVS can be thought of as valuation peers to MEDP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...